Miquel D. Ferrer
Expertise in
4
conditions

Miquel D. Ferrer

Villarroel St. 170, 
Barcelona, CT, ES 
Expertise in
4
conditions
Villarroel St. 170, 
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Miquel Ferrer practices in Barcelona, Spain. Mr. Ferrer is highly rated in 4 conditions, according to our data. His top areas of expertise are Pneumonia, Hospital-Acquired Pneumonia, Acute Respiratory Distress Syndrome (ARDS), and Methicillin-Resistant Staphylococcus Aureus (MRSA).

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Villarroel St. 170, Barcelona, CT 08036, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other, Drug
Study Drug: Allocetra-OTS
Study Phase: Phase 2
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Biological, Other
Study Drug: Cx611
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

109 Total Publications

Comparative analysis of illumina and oxford nanopore sequencing platforms for 16S rRNA profiling of respiratory microbial communities.
Comparative analysis of illumina and oxford nanopore sequencing platforms for 16S rRNA profiling of respiratory microbial communities.
Journal: Scientific reports
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ferrer's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile